1. Search Result
Search Result
Results for "

thrombocytopenia

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

2

Peptides

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147005

    CRAC Channel Cardiovascular Disease
    piCRAC-1 is a potent, photoinducible Ca 2+ release-activated Ca 2+ (CRAC) channel inhibitor. piCRAC-1 alleviates thrombocytopenia and hemorrhage .
    piCRAC-1
  • HY-122620

    Thrombopoietin Receptor Inflammation/Immunology Cancer
    Hetrombopag is a potent thrombopoietin receptor agonist. Hetrombopag is efficacious and well tolerated with a manageable safety profile. Hetrombopag has the potential for the research of immune thrombocytopenia .
    Hetrombopag
  • HY-145598

    HMPL-523

    Syk Cancer
    Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP) .
    Sovleplenib
  • HY-112995

    Thrombin Inflammation/Immunology
    Lepirudin is a potent irreversible thrombin inhibitor. Lepirudin also is a recombinant hirudin. Lepirudin has anticoagulation in heparin-induced thrombocytopenia (HIT) .
    Lepirudin
  • HY-109549

    CGP 39393; Revasc

    Thrombin Cardiovascular Disease
    Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction .
    Desirudin
  • HY-15306S
    Eltrombopag-13C4
    1 Publications Verification

    SB-497115-13C4

    Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag- 13C4 (SB-497115- 13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .
    Eltrombopag-13C4
  • HY-15306
    Eltrombopag
    Maximum Cited Publications
    10 Publications Verification

    SB-497115

    Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag
  • HY-B1080
    Tilorone dihydrochloride
    1 Publications Verification

    HIF/HIF Prolyl-Hydroxylase Influenza Virus Infection Neurological Disease
    Tilorone dihydrochloride is an orally active interferon (IFN) inducer with broad-spectrum antiviral activities. Tilorone dihydrochloride possesses robust anti-Severe fever with thrombocytopenia syndrome virus (SFTSV) activity in vitro and in vivo through stimulation of host innate immunity. Tilorone dihydrochloride can penetrate the blood-brain barrier to activate HIF in the CNS .Tilorone dihydrochloride exhibits an inhibitory activity with EC50 of 230 nM against Ebola virus (EBOV) .
    Tilorone dihydrochloride
  • HY-15306A
    Eltrombopag Olamine
    Maximum Cited Publications
    10 Publications Verification

    Eltrombopag diethanolamine salt; SB-497115GR

    Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag Olamine
  • HY-B1212
    Broxyquinoline
    1 Publications Verification

    Dibromohydroxyquinoline; 5,7-Dibromo-8-hydroxyquinoline

    Parasite Infection
    Broxyquinoline (Dibromohydroxyquinoline) is a potent severe fever with thrombocytopenia syndrome virus (SFTSV) inhibitor with an IC50 of 5.8 µM. Broxyquinoline is an antiprotozoal agent .
    Broxyquinoline
  • HY-153239

    Thrombopoietin Receptor Inflammation/Immunology
    Eltrombopag methyl ester is a derivative of Eltrombopag, which is a thrombopoietin (Tpo) receptor agonist, which can promote platelet production and is used in research related to specific types of thrombocytopenia .
    Eltrombopag methyl ester
  • HY-100380

    Thrombopoietin Receptor Cardiovascular Disease
    TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia .
    TPO agonist 1
  • HY-121377

    Platelet-activating Factor Receptor (PAFR) Inflammation/Immunology Cancer
    Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells) .
    Epiyangambin
  • HY-P3012

    Cathepsin Inflammation/Immunology
    Cathepsin G acts as a potent agonist of human platelet activation leading to their aggregation., and can be used for screening of relevant inhibitors .
    Cathepsin G
  • HY-153953

    Bcl-2 Family Cancer
    Bcl-2-IN-11 (compound 6) is a potent and selective Bcl-2 activity inhibitor, with an IC50 of 0.9 nM. Bcl-2-IN-11 shows weak inhibition of Bcl-xl (IC50 > 1000 nM). Bcl-2-IN-11 can be used for the research of a variety of cancers caused by abnormal overexpression of Bcl-2 family proteins: especially malignant hematologic diseases of acute lymphoid leukemia, etc. Bcl-2-IN-11 can also avoid toxic side effects caused by Bcl-xl inhibition, such as thrombocytopenia .
    Bcl-2-IN-11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: